Two phase, open-label, sequential, ascending dose study of the tolerability, safety, and pharmacokinetics of CRA-024781 [PCI 24781] in cancer patients
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Abexinostat (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Pharmacyclics
- 20 Aug 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 13 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
- 15 Feb 2006 New trial record.